ALKS · Alkermes plc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $219.5M | Six Months Ended June 30, 2026 | — |
|
|
|||
| LYBALVI revenue growth | 12% | Q2 2026 | — |
|
|
|||
| LYBALVI total prescriptions growth | 18% | Q2 2026 | — |
|
|
|||
| Total Proprietary Net Sales | $411.72M | FY2026 Q2 | +34.0% |
|
|
|||
| EBITDA | $285.6M | Twelve Months Ended December 31, 2025 | — |
| EBITDA From Continuing Operations | $285.6M | Twelve Months Ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALKS
this stock
Alkermes plc.
|
$8.32B | +77.3% | -5.2% | 130.6 | 9.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$53.75B | +6.2% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$51.44B | +4.5% | — | — | 0.0% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$45.13B | — | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.71B | -2.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALKS | +2.6% | -8.6% | +42.1% | +1.3% | +77.3% |
| SPY | +4.1% | +3.2% | +11.4% | +3.3% | +13.1% |
| vs SPY | -1.5% | -11.8% | +30.7% | -2.0% | +64.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.